KimTIVartanianSSSchneiderPA.A review and proposed classification system for the no-option patient with chronic limb-threatening ischemia. J Endovasc Ther. 2021;28(2):183–193. doi:10.1177/1526602820963911.
2.
Mohamad YusoffFKajikawaMSakamotoT, et alLow-intensity pulsed ultrasound for “no-option” chronic/critical limb-threatening ischaemia in a patient with Buerger disease: a case report. Eur Heart J Case Rep. 2024;8(6):ytae246. doi:10.1093/ehjcr/ytae246.
3.
BenforBCsoreJVelaDC, et alMagnetic resonance imaging and histological insights into deep venous arterialisation. EJVES Vasc Forum. 2024;61:121–125. doi:10.1016/j.ejvsvf.2024.04.003.
4.
FangYLiuHPanT, et alEvaluation of the lower extremity blood supply in no-option critical limb ischemia patients with stem cell transplantation by time maximum intensity projection CT perfusion: a single-centre prospective study. Vascular. 2024;32(5):1159–1167. doi:10.1177/17085381231192852.
5.
SainiNMarroneLDesaiS, et alComparison of outcomes of percutaneous deep venous arterialization in multiple practice settings. J Vasc Surg. 2024;80(5):1507–1514. doi:10.1016/j.jvs.2024.05.051.
6.
AshoobiMTHemmatiHAghayanHR, et alWharton’s jelly mesenchymal stem cells transplantation for critical limb ischemia in patients with type 2 diabetes mellitus: a preliminary report of phase I clinical trial. Cell Tissue Res. 2024;395(2):211–220. doi:10.1007/s00441-023-03854-7.
7.
ShanmugasundaramSHermanKRundbackJH.Percutaneous deep venous arterialization in patients with no-option critical limb ischemia performed in an office-based laboratory setting. J Vasc Interv Radiol. 2024;35(2):278–284. doi:10.1016/j.jvir.2023.10.003.
8.
Randial-PérezLJPortilla-RojasEPinzón-PintoM, et alOpen distal venous arterialization technique as an opportunity for patients with critical limb ischemia: a Latin American experience. Vasc Endovascular Surg. 2025;59(4):428–434. doi:10.1177/15385744241306497.
9.
RehakLGiuratoLMonamiM, et alThe immune-centric revolution translated into clinical application: peripheral blood mononuclear cell (PBMNC) therapy in diabetic patients with no-option critical limb-threatening ischemia (NO-CLTI)-rationale and meta-analysis of observational studies. J Clin Med. 2024;13(23):7230. doi:10.3390/jcm13237230.
10.
DesaiSSharmaDSrinivasR, et alMesenchymal stromal cell therapy (REGENACIP®), a promising treatment option in chronic limb threatening ischemia—a narrative review. Stem Cell Res Ther. 2024;15(1):352. doi:10.1186/s13287-024-03957-0.
11.
SojakovaDHusakovaJFejfarovaV, et alThe use of autologous cell therapy in diabetic patients with chronic limb-threatening ischemia. Int J Mol Sci. 2024;25(18):10184. doi:10.3390/ijms251810184.
12.
HuangINakamaTIchihashiS, et alTechnical aspects of percutaneous deep venous arterialization using off-the-shelf devices. J Endovasc Ther. 2024;31(3):350–359. doi:10.1177/15266028221127850.
13.
KukharchukOBopardikarAAnand BaskaranPP, et alFetal progenitor cells for treatment of chronic limb ischemia. Am J Stem Cells. 2024;13(3):169–190. doi:10.62347/MZKI8393.
14.
RoustazadehRGombertAKrabbeJ, et alShort-term outcomes and efficacy of percutaneous deep vein arterialization for no-option critical limb ischemia: a systematic review and meta-analysis. Biomedicines. 2024;12(2):318. doi:10.3390/biomedicines12020318.
15.
SetiaOLeeSRDardikA.Modalities to deliver cell therapy for treatment of chronic limb threatening ischemia. Adv Wound Care. 2024;13(5):253–279. doi:10.1089/wound.2022.0114.
